Prescription for Better Access

Mark Hansan and Dr. Scott Howell
  • 5.0 (16)
  • MEDICINE
  • UPDATED BIWEEKLY
Prescription for Better Access Podcast

With pharmaceutical and biotech manufacturers launching more high-cost specialty drugs and the insurance industry increasing the use of more restrictive barriers to access, those who need these medicines—the patients themselves—are caught in the middle, not only shouldering the cost of higher copays and deductibles, but for many, rationing or even abandoning treatment altogether. While manufacturers invest in programs to help navigate the challenges impeding access and affordability, the entire healthcare industry can agree -- the status quo is unsustainable. There has to be a better way. And two industry veterans have joined forces to co-host a new interview-focused podcast to help shape the future of patient access and affordability.

  1. AUG 20

    Evolution of PBM's

    In this episode, we explore the evolution and future of the Pharmacy Benefit Management (PBM) industry with insights from two seasoned pharma managed care executives. We discuss the early role of PBMs, their acquisition by pharmaceutical companies, and subsequent industry consolidation. We examine how vertical integration of the PBMs transformed their business model, including the restricted formularies that gave rise to rebates. We also address evolving PBM-manufacturer relationships, the effects of public scrutiny, and predictions for key trends. Join us for a comprehensive look at the past, present, and future of PBMs, focusing on the changes needed to better serve patients. Steve Stefano, Managing Director, ReprizioRx  Steve.Stefano@repriziorx.com Bill Leonard, Managing Director, ReprizioRX wjl@repriziorx.com ReprizioRX PBMs IPA model HMO Medco Metro Containment Services Medicare Catastrophic Coverage Act of 1988 Merck SmithKline Beecham Eli Lilly 340B NDC blocks Group Purchasing Organizations (GPOs)  Medicare United Healthcare FTC CostPlusDrugs Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    45 min

  2. JUL 16

    How Access Challenges Impact the Drug Development Pipeline

    In this episode, we dive into the pharmaceutical industry's research and drug development side and the real threat that today’s access and affordability challenges and policies pose to innovation. While innovation often starts in universities with government support, biotech, and pharma companies take on the tough, costly job of clinical trials, development, and approval of new drugs. Investment dollars are limited, only the most promising projects get funded, with an expectation there will be a return. However, our current drug payment process and policies like the IRA have added new considerations for investors, risking fewer new drugs being developed. Without changes, patients could face the closing of our nation's medicine cabinet, with fewer new treatments available. This would be an outcome that would be catastrophic for all of us. Erin Mistry, EVP and Chief Commercial Officer, Cormedix, Inc. Imran Nasrullah, JD., formerly VP & US Head of BD&L at Bayer, and now Founder, SNAP Life Sciences Research and development (R&D) FDA CF Foundation Vertex NIH AMR (antimicrobial resistance) The Pasteur Act HIV Malaria Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy. Genentech Genzyme (Now Sanofi) Medicare IRA (Inflation Reduction Act) COVID-19 Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    49 min

  3. JUN 4

    Interviews from Asembia’s AXS24 Summit, Part 2

    This is the second of two episodes dedicated to Asembia’s AXS24 Summit, where we were honored to be a media partner. In this episode, we learn from Sarah Butler, Chief Commercial Officer of ADVI Health and Lindsay Greenleaf, JD, MBA, Head of Federal and State Policy for ADVI Health how the 2024 election will impact patient access and affordability. Umar Afridi, Founder and CEO of Foundation Health, summarizes his session, From Opaque to Transparent: Transforming the Way We Pay for Drugs. Finally, we get a few minutes with Joe Boswell, the President of ACCESS Forum, leading an effort to create a network for market access professionals. ADVI: Sarah Butler (Chief Commercial Officer) Lindsey Greenleaf (Consulting and Government Affairs Head) R&D Inflation Reduction Act NCCN Compendia Part D CMS Pharmacy Benefit Managers (PBMs) Part B FTC and Office of Inspector General (IG) FTC's Section 6B study Foundation Health:Umar Afridi, Founder and CEO Session: "From Opaque to Transparent: Transforming the Way We Pay for Drugs." Pharmacy Benefit Managers (PBMs) Truepill API platforms International Access Professional Society:Joe Boswell. President GenMAV Asembia

    34 min

  4. MAY 24

    Interviews from Asembia's AXS24 Summit, Part 1 of 2

    Asembia’s AXS24 Summit, a pinnacle of specialty drug and healthcare discussions, concluded earlier this month. We are thrilled to share that our podcast was selected as a media partner for this esteemed event. This is the first of two episodes dedicated to AXS24, where Scott and Mark had the opportunity to interview several key speakers and attendees. In this episode, we bring you the insights of Melissa Paige, a seasoned healthcare professional and President of the National Association of Medication Access & Patient Advocacy, who led a session on the Patient Financial Impact of IRA. We also present the perspectives of Renee Rayburg, RPh., VP, Clinical Strategy, Pharmaceutical Strategy Group and Morgan Lee, PhD, MPH, CPH, Senior Director, Research & Strategy, PSG, who are renowned for their study and session on Viewpoints in Specialty Drug Benefit Design. Melissa Paige, President, (NAMAPA) University of Virginia Health System Asembia Inflation Reduction Act Dr. Madelaine Feldman Renee Rayburg, Vice President Specialty Clinical Consulting, Artemetrx,  Morgan Lee, PhD, Senior Director, PSG Pharmacy Benefit Managers (PBMs) GoodRx 2024 Trends in Specialty Drug Benefits Report Medical terminology referenced in this episode: Generic ARBs Multiple Sclerosis Humira biosimilars Albuterol inhaler Email us:comments@prescriptionforbetteraccess.com. Follow us on X, LinkedIn, YouTube and Threads.

    36 min

  5. APR 25

    Understanding 340B Programs: An Interview with Antonio Ciaccia, CEO, 46brooklyn Research

    In this episode, we explore the 340B Drug Pricing Program, an essential yet complex component of the American drug supply landscape that aims to enable healthcare entities to offer more affordable medication to underserved populations. We interview Antonio Ciaccia, a drug pricing and 340B expert who provides an in-depth look at how the program works, its financial incentives, and how stakeholders have exploited this well-intentioned program, all to the detriment of patients. Antonio Ciaccia, President, 3 Axis Advisors and CEO, 46brooklyn Research, an Ohio non-profit Corporation 46brooklyn Ohio Pharmacist Association 3 Axis Advisors Medicaid 340B Program 340B Litigation 340 Eligibility, HRSA Covered Entities Medicaid Drug Rebate Program Obamacare Indian Health Service "Money from Sick People," Report from 46Brooklyn Medicare Pharmacy Benefit Managers (PBMs) Jamie Robinson, Health Economist Medical terminology referenced in this episode: Novolog Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    47 min

  6. MAR 28

    Interview with Victor Bulto, President, US, Novartis

    In this important podcast episode, we interview Victor Bulto, President, US for Novartis, to discuss the company's efforts to develop groundbreaking treatments while ensuring accessibility and affordability for patients. We delve into how the pharmaceutical industry navigates numerous post-FDA approval barriers to launch new drugs and the importance of market access, patient support services, and a commitment by manufacturers to provide patient assistance and other support for patients. Victor Bulto, President, Novartis Novartis FDA Institute for Clinical and Economic Review (ICER) American Heart Association (AHA) Inflation Reduction Act (IRA) Pharmacy Benefit Manager (PBM) Medicare Medical terminology referenced in this episode: Cell therapy: CART-T  Radioligand therapy RNA Entresto Molecular glues Targeted protein degradation Antisense oligonucleotides Small interfering RNAs: siRNAs LDL cholesterol COVID Hematological malignancies Refractory autoimmune diseases Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    44 min

  7. FEB 27

    Biosimilar's Role in Improving Patient Access

    Biosimilars are entering the market at their fastest pace ever. In this episode, we interview a renowned health economist and an expert consultant in biosimilar distribution and patient support to explore the complex landscape of biosimilars, including examining the hurdles and breakthroughs in achieving acceptance by payers and providers and how best to improve patient access and affordability in a market dominated by established brands. Dr. Jason Shafrin, Senior Managing Director, Center for Healthcare Economics and Policy at FTI Consulting Marina Allen, SVP, Fingerpaint Market Access, Patient Support & Access Strategy Leader in Pharma-Biotech Biosimilars The Biologics Price Competition and Innovation Act of 2009 PBMs (Pharmacy Benefit Managers) Medicare Advantage Humira (biosimilars) 340B program Inflation Reduction Act Medicare Part D "brown bagging and white bagging" Mark Cuban (CostPlusDrugs) GoodRx average sales price (ASP) electronic health record (EHR) system Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    43 min

  8. JAN 30

    2024 Policy Preview: An Interview with Dr. Mark McClellan

    Scott and Mark welcome Dr. Mark McClellan, a distinguished health policy expert who has served as the Commissioner of the FDA and the Administrator of CMS, to look ahead at the major policy activities in 2024. They discuss how the government's role as regulator and purchaser of drugs will influence the drug industry and the patient's ability to access and afford medicines this year. They also discuss the challenges and opportunities for improving public health and the emerging role of artificial intelligence. Dr. Mark McClellan, PhD, Director and Professor of Business, Medicine and Policy at the Duke-Margolis Center for Health Policy at Duke University IRA Medicare Part D Pharmacy Benefit Managers (PBMs) Medicare Advantage FDA commissioner Rob Califf  The Ryan White HIV/AIDS Program (RWHAP) Part B Medicare Modernization Act FDA FDA's Office of Regulatory Affairs Centers for Medicare & Medicaid Services (CMS)  Centers for Disease Control and Prevention (CDC) Per Member Per Month (PMPM) billing  Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    50 min
See All (23)

5
out of 5
16 Ratings

About

With pharmaceutical and biotech manufacturers launching more high-cost specialty drugs and the insurance industry increasing the use of more restrictive barriers to access, those who need these medicines—the patients themselves—are caught in the middle, not only shouldering the cost of higher copays and deductibles, but for many, rationing or even abandoning treatment altogether. While manufacturers invest in programs to help navigate the challenges impeding access and affordability, the entire healthcare industry can agree -- the status quo is unsustainable. There has to be a better way. And two industry veterans have joined forces to co-host a new interview-focused podcast to help shape the future of patient access and affordability.

Information

  • Creator
    Mark Hansan and Dr. Scott Howell
  • Years Active
    2023 - 2024
  • Episodes
    23
  • Rating
    Clean
  • Copyright
    © 2024 Prescription for Better Access Mark Hansan and Dr. Scott Howell
  • Show Website
    Prescription for Better Access

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada